Clinical Trial Update: Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks [Phase 4]

View source ↗

Summary

Long-term, open-label Phase 4 study assessing cardiovascular risks in multiple sclerosis patients has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2021-02-10